

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1614

OKUNO ET AL.

APPLICATION NO: 10/807,736

FILED: MARCH 24, 2004

FOR: USE OF BISPHOSPHONIC ACIDS FOR TREATING  
ANGIOGENESIS

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

FEE LETTER


Sir:

Enclosed herewith is a Terminal Disclaimer in the above-identified application.

The Commissioner is hereby authorized to charge the \$130 fee under 37 CFR §1.20(d) and any additional fees that may be required to Deposit Account No. 19-0134 in the name of Novartis. An additional copy of this paper is here enclosed.

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7852  
Date: 12/4/07

  
\_\_\_\_\_  
Oona A. Manzari  
Attorney for Applicants  
Reg. No. 48,152